Jessie Denzin
Family · Lenexa, KSNPI 1982329249
Payments from drug & device makers
Across 99 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$297
- Lilly USA, LLC$221
- Novo Nordisk$203
- AstraZeneca$170
- Pfizer$169
- Radius Health, Inc.$162
- plus $679 from 15 others
What the payments were for
- Food & beverage$1,901100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $297 |
| Lilly USA, LLC | 11 | $221 |
| Novo Nordisk | 14 | $203 |
| AstraZeneca | 11 | $170 |
| Pfizer | 10 | $169 |
| Radius Health, Inc. | 6 | $162 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $83 |
| GSK | 5 | $82 |
| Noven Therapeutics, LLC | 4 | $80 |
| Amgen | 4 | $67 |
| Astellas Pharma US Inc | 2 | $55 |
| Organon | 2 | $54 |
| Bayer | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 3 | $43 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Merck | 2 | $33 |
| Boston Scientific | 1 | $32 |
| Eisai Inc. | 1 | $21 |
| Novartis | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
How this compares
$1,901 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 31 | $36,135 |
| OzempicSemaglutide | 27 | $25,742 |
| TrulicityDulaglutide | 16 | $15,806 |
| Eszopiclone | 21 | $1,680 |
| Atorvastatin Calcium | 155 | $1,245 |
| Tramadol Hcl | 49 | $724 |
| Bupropion XlBupropion Hcl | 24 | $687 |
| Levothyroxine Sodium | 78 | $503 |
| Losartan Potassium | 69 | $487 |
| Lisinopril | 98 | $480 |
| Tamsulosin Hcl | 22 | $440 |
| Rosuvastatin Calcium | 38 | $398 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $385 |
| Simvastatin | 42 | $369 |
| Fluticasone Propionate | 17 | $342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $221 | $51,94147 claims |
| Novo NordiskOzempic | $203 | $25,74227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,579 family providers in Kansas.
Other family in Lenexa
- Jennifer AndersonLenexa$9K
- Anna CattauLenexa$7K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.